Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Journal of Translational Medicine
Published in: Journal of Translational Medicine 1/2014

Open Access 01-12-2014 | Research

Up-regulation of heme oxygenase-1 after infarct initiation reduces mortality, infarct size and left ventricular remodeling: experimental evidence and proof of concept

Authors: Claudia Kusmic, Cristina Barsanti, Marco Matteucci, Nicoletta Vesentini, Gualtiero Pelosi, Nader G Abraham, Antonio L’Abbate

Published in: Journal of Translational Medicine | Issue 1/2014

Login to get access

Abstract

Background

Up-regulation of HO-1 by genetic manipulation or pharmacological pre-treatment has been reported to provide benefits in several animal models of myocardial infarction (MI). However, its efficacy following MI initiation (as in clinical reality) remains to be tested. Therefore, this study investigated whether HO-1 over-expression, by cobalt protoporphyrin (CoPP) administered after LAD ligation, is still able to improve functional and structural changes in left ventricle (LV) in a rat model of 4-week MI.

Methods

A total of 144 adult male Wistar rats were subjected to either left anterior coronary artery ligation or sham-operation. The effect of CoPP treatment (5 mg/kg i.p. at the end of the surgical session and, then, once a week for 4 weeks) was evaluated on the basis of survival, electro- and echocardiography, plasma levels of B-type natriuretic peptide (BNP), endothelin-1 and prostaglandin E2, coronary microvascular reactivity, MI size, LV wall thickness and vascularity. Besides, the expression of HO-1 and connexin-43 in different LV territories was assessed by western blot analysis and immunohistochemistry, respectively.

Results

CoPP induced an increased expression of HO-1 protein with >16 h delay. CoPP treatment significantly reduced mortality, MI size, BNP concentration, ECG alterations, LV dysfunction, microvascular constriction, capillary rarefaction and restored connexin-43 expression as compared to untreated MI. These functional and structural changes were paralleled by increased HO-1 expression in all LV territories. HO activity inhibition by tin-mesoporphyrin abolished the differences between CoPP-treated and untreated MI animals.

Conclusions

This is the first report demonstrating the putative role of pharmacological induction of HO-1 following coronary occlusion to benefit infarcted and remote territories, leading to better cardiac function in a 4-week MI outcome.
Appendix
Available only for authorised users
Literature
1.
Vaughan DE, Pfeffer MA: Angiotensin converting enzyme inhibitors and cardiovascular remodelling. Cardiovasc Res. 1994, 28: 159-165. 10.1093/cvr/28.2.159.CrossRefPubMed
2.
Solomon SD, Skali H, Anavekar NS, Bourgoun M, Barvik S, Ghali JK, Warnica JW, Khrakovskaya M, Arnold JM, Schwartz Y, Velazquez EJ, Califf RM, McMurray JV, Pfeffer MA: Changes in ventricular size and function in patients treated with valsartan, captopril, or both after myocardial infarction. Circulation. 2005, 111: 3411-3419. 10.1161/CIRCULATIONAHA.104.508093.CrossRefPubMed
3.
Koitabashi N, Kass DA: Reverse remodeling in heart failure mechanisms and therapeutic opportunities. Nat Rev Cardiol. 2011, doi:10.1038/nrcardio.2011.172
4.
Cleutjens JPMW, Blankesteijn MW, Daemen MJAP, Smits JFM: The infarcted myocardium: simply dead tissue, or a lively target for therapeutic interventions. Cardiovasc Res. 1999, 44: 232-241. 10.1016/S0008-6363(99)00212-6.CrossRefPubMed
5.
Nian M, Lee P, Khaper N, Liu P: Inflammatory cytokines and postmyocardial infarction remodeling. Circ Res. 2004, 94: 1543-1553. 10.1161/01.RES.0000130526.20854.fa.CrossRefPubMed
6.
7.
8.
Pelosi G, Matteucci M, Kusmic C, Vesentini N, Piccolomini F, Viglione F, Trivella MG, L’Abbate A: Time course of TUNEL nuclear positivity of cardiomyocytes in a chronic rat model of coronary occlusion with and without reperfusion. Cardiovasc Res. 2010, 87: S76-
9.
Whelan RS, Kaplinskiy V, Kitsis RN: Cell death in the pathogenesis of heart disease: mechanisms and significance. Ann Rev Physiol. 2010, 72: 19-44. 10.1146/annurev.physiol.010908.163111.CrossRef
10.
Yet SF, Tian R, Layne MD, Wang ZY, Maemura K, Solovyeva M, Ith B, Melo LG, Zhang L, Ingwall JS, Dzau VJ, Lee ME, Perrella MA: Cardiac-specific expression of heme oxygenase-1 protects against ischemia and reperfusion injury in transgenic mice. Circ Res. 2001, 89: 168-173. 10.1161/hh1401.093314.CrossRefPubMed
11.
Wang G, Hamid T, Keith RJ, Zhou G, Partridge CR, Xiang X, Kingery JR, Lewis RK, Li Q, Rokosh DG, Ford R, Spinale FG, Riggs DW, Srivastava S, Bhatnagar A, Bolli R, Prabhu SD: Cardioprotective and antiapoptotic effects of heme oxygenase-1 in the failing heart. Circulation. 2010, 121: 1912-1925. 10.1161/CIRCULATIONAHA.109.905471.PubMedCentralCrossRefPubMed
12.
Juhasz B, Varga B, Czompa A, Bak I, Lekli I, Gesztelyi R, Zsuga J, Kemeny-Beke A, Antal M, Szendrei L, Tosaki A: Postischemic cardiac recovery in heme oxygenase-1 transgenic ischemic/reperfused mouse myocardium. J Cell Mol Med. 2011, 15: 1973-1982. 10.1111/j.1582-4934.2010.01153.x.PubMedCentralCrossRefPubMed
13.
Melo LG, Agrawal R, Zhang L, Rezvani M, Mangi AA, Ehsan A, Griese DP, Dell’Acqua G, Mann MJ, Oyama J, Yet SF, Layne MD, Perrella MA, Dzau VJ: Gene therapy strategy for long-term myocardial protection using adenoassociated virus-mediated delivery of heme oxygenase gene. Circulation. 2002, 105: 602-607. 10.1161/hc0502.103363.CrossRefPubMed
14.
Liu X, Pachori AS, Ward CA, Davis JP, Gnecchi M, Kong D, Zhang L, Murduck J, Yet SF, Perrella MA, Pratt RE, Dzau VJ, Melo LG: Heme oxygenase-1 (HO-1) inhibits postmyocardial infarct remodeling and restores ventricular function. FASEB J. 2006, 20: 207-216. 10.1096/fj.05-4435com.CrossRefPubMed
15.
Liu X, Simpson JA, Brunt KR, Ward CA, Hall SR, Kinobe RT, Barrette V, Tse MY, Pang SC, Pachori AS, Dzau VJ, Ogunyankin KO, Melo LG: Preemptive heme oxygenase-1 gene delivery reveals reduced mortality and preservation of left ventricular function 1 yr after acute myocardial infarction. Am J Physiol Heart Circ Physiol. 2007, 293: H48-H49. 10.1152/ajpheart.00741.2006.CrossRefPubMed
16.
Lakkisto P, Kytö V, Forsten H, Siren JM, Segersvärd H, Voipio-Pulkki LM, Tikkanen I: Heme oxygenase-1 and carbon monoxide promote neovascularization after myocardial infarction by modulating the expression of HIF-1alpha, SDF-1alpha and VEGF-B. Eur J Pharmacol. 2010, 635: 156-164. 10.1016/j.ejphar.2010.02.050.CrossRefPubMed
17.
18.
Smith A, Alam J, Escriba PV, Morgan WT: Regulation of heme oxygenase and metallothionein gene expression by the heme analogs, cobalt-, and tin-protoporphyrin. J Biol Chem. 1993, 268: 7365-7371.PubMed
19.
Lin HH, Chen YH, Chang PF, Lee YT, Yet SF, Chau LY: Heme oxygenase-1 promotes neovascularization in ischemic heart by coinduction of VEGF and SDF-1. J Mol Cell Cardiol. 2008, 45: 44-55. 10.1016/j.yjmcc.2008.04.011.CrossRefPubMed
20.
Sardana MK, Kappas A: Dual control mechanism for heme oxygenase: Tin (IV)-protoporphyrin potently inhibits enzyme activity while markedly increasing content of enzyme protein in liver. Proc Natl Acad Sci U S A. 1987, 84: 2464-2468. 10.1073/pnas.84.8.2464.PubMedCentralCrossRefPubMed
21.
Delaney JK, Mauzerall D, Drummond GS, Kappas A: Photophysical properties of Sn-porphyrins: potential clinical implications. Pediatrics. 1988, 81: 498-504.PubMed
22.
DeSandre GH, Wong RJ, Morioka I, Contag CH, Stevenson DK: The effectiveness of oral tin mesoporphyrin prophylaxis in reducing bilirubin production after an oral heme load in a transgenic mouse model. Biol Neonat. 2005, 89: 139-146.CrossRef
23.
Kim DH, Burgess AP, Li M, Tsenovoy PL, Addabbo F, McClung JA, puri N, Abraham NG: Heme oxygenase-mediated increases in adiponectin decrease fat content and inflammatory cytokines tumor necrosis factor-alpha and interleukin-6 in Zucker rats and reduce adipogenesis in human mesenchymal stem cells. J Pharmacol Exp Ther. 2008, 325: 833-840. 10.1124/jpet.107.135285.CrossRefPubMed
24.
Walker MJ, Curtis MJ, Hearse DJ, Campbell RW, Janse MJ, Yellon DM, Cobbe SM, Coker SJ, Harness JB, Harron DW, Higgins AJ, Julian DG, Lab MJ, Manning AS, Northover BJ, Parratt JR, Riemersma RA, Riva E, Russell DC, Sheridan DJ, Winslow E, Woodward B: The Lambeth Conventions: guidelines for the study of arrhythmias in ischemia, infarction, and reperfusion. Cardiovasc Res. 1988, 22: 447-455. 10.1093/cvr/22.7.447.CrossRefPubMed
25.
Demiryurek AT, Yildiz G, Esiyok S, Altug S: Protective effects of poly (ADP-ribose) synthase inhibitors on digoxin-induced cardiotoxicity in guinea-pig isolated hearts. Pharmacol Res. 2002, 45: 189-194. 10.1006/phrs.2002.0945.CrossRefPubMed
26.
Miranda A, Costa-E-Sousa RH, Werneck-De-Castro JPS, Mattos EC, Olivares EL, Ribeiro VP, Silva MG, Goldenberg R, Campos-de-Carbalho AC: Time course of echocardiographic and electrocardiographic parameters in myocardial infarct in rats. Ann Braz Acad Sci. 2007, 70: 639-648.CrossRef
27.
Pousset F, Isnard R, Lechat P, Kalotka H, Carayon A, Maistre G, Escolano S, Thomas D, Komajda M: Prognostic value of plasma endothelin-1 in patients with chronic heart failure. Eur Heart J. 1997, 18: 254-258. 10.1093/oxfordjournals.eurheartj.a015228.CrossRefPubMed
28.
Moe GW, Rouleau JL, Nguyen QT, Cernacek P, Stewart DJ: Role of endothelins in congestive heart failure. Can J Physiol Pharmacol. 2003, 81: 588-597. 10.1139/y03-011.CrossRefPubMed
29.
Degousee N, Fazel S, Angoulvant D, Stefanski E, Pawelzik SC, Korotkova M, Arab S, liu P, Lindsay TF, Zhuo S, Butany J, Li RK, Audoly L, Schmidt R, Angioni C, Geisslinger G, Jakobsson PJ, Rubin BB: Microsomal prostaglandin E2 synthase-1 deletion leads to adverse left ventricular remodeling after myocardial infarction. Circulation. 2008, 117: 1701-1710. 10.1161/CIRCULATIONAHA.107.749739.CrossRefPubMed
30.
Kusmic C, Lazzerini G, Coceani F, Barsacchi R, L'Abbate A, Sambuceti G: Paradoxical coronary microcirculatory constriction during ischemia: a synergic function for nitric oxide and endothelin. Am J Physiol Heart Circ Physiol. 2006, 291: H1814-H1821. 10.1152/ajpheart.00220.2006.CrossRefPubMed
31.
Motterlini R, Foresti R, Intaglietta M, Winslow RM: NO-mediated activation of heme oxygenase: Endogenous cytoprotection against oxidative stress to endothelium. Am J Physiol Heart Circ Physiol. 1996, 270: H107-H114.
32.
Pfeffer MA, Pfeffer JM, Fishbein MC, Fletcher PJ, Spadaro J, Kloner RA, Braunwald E: Myocardial infarct size and ventricular function in rats. Circ Res. 1979, 44: 503-512. 10.1161/01.RES.44.4.503.CrossRefPubMed
33.
Chen L, Chen CX, Gan XT, Beier N, Scholz W, Karmazyn M: Inhibition and reversal of myocardial infarction-induced hypertrophy and heart failure by NHE-1 inhibition. Am J Physiol Heart Circ Physiol. 2004, 286: H381-H387.CrossRefPubMed
34.
Hou Y, Huang C, Cai X, Zhao J, Guo W: Improvements in the establishment of a rat myocardial infarction model. J Int Med Res. 2011, 39: 1284-1292. 10.1177/147323001103900416.CrossRefPubMed
35.
De Serro-Azul LG, Moffa PJ, Mignone CA, De Carvalho Filho ET, Pileggi F, Tranchesi J: Vectorcardiographic diagnosis of left anterior divisional block in myocardial infarct. Rev Paul Med. 1974, 83: 267-273.PubMed
36.
Santos PEB, Masuda MO: The electrocardiogram of rats with an old extensive myocardial infarction. Braz J Med Biol Res. 1991, 24: 1173-1177.PubMed
37.
Spragg DD, Akar FG, Helm RH, Tunin RS, Tomaselli GF, Kass DA: Abnormal conduction and repolarization in late-activated myocardium of dyssynchronously contracting hearts. Cardiovasc Res. 2005, 67: 77-86. 10.1016/j.cardiores.2005.03.008.CrossRefPubMed
38.
Thomas SA, Schuessler RB, Berul CI, Beardslee MA, Beyer EC, Mendelsohn ME, Saffitz JE: Disparate effects of deficient expression of connexin43 on atrial and ventricular conduction evidence for chamber-specific molecular determinants of conduction. Circulation. 1998, 97: 686-691. 10.1161/01.CIR.97.7.686.CrossRefPubMed
39.
Jalife J, Morley GE, Vaidya D: Connexin and impulse propagation in the mouse heart. J Cariovasc Electrophysiol. 1999, 10: 1649-1663. 10.1111/j.1540-8167.1999.tb00230.x.CrossRef
40.
Danik SB, Liu F, Zhang J, Suk HJ, Morley GE, Fishman GI, Gutstein DE: Modulation of cardiac gap junction expression and arrhythmic susceptibility. Circ Res. 2004, 95: 1035-1041. 10.1161/01.RES.0000148664.33695.2a.PubMedCentralCrossRefPubMed
41.
Morley GE, Danik SB, Bernstein B, Sun Y, Rosner G, Gutstein DE, Fishman GI: Reduced intercellular coupling leads to paradoxical propagation across the Purkinje-ventricular junction and aberrant myocardial activation. Proc Natl Am Soc. 2005, 102: 4126-4129. 10.1073/pnas.0500881102.CrossRef
42.
Bacharova L, Plandorova J, Klimas J, Krenek P, Kyselovic J: Discrepancy between increased left ventricular mass and “normal” QRS voltage is associated with decreased connexin 43 expression in early stage of left ventricular hypertrophy in spontaneously hypertensive rats. J Electrocardiol. 2008, 41: 730-734. 10.1016/j.jelectrocard.2008.01.013.CrossRefPubMed
43.
Guerrero PA, Schuessler RB, Davis LM, Beyer EC, Johnson CM, Yamada KA, Saffitz JE: Slow ventricular conduction in mice heterozygous for a connexin43 null mutation. J Clin Invest. 1997, 99: 1991-1998. 10.1172/JCI119367.PubMedCentralCrossRefPubMed
44.
Yuan MJ, Huang H, Tang YH, Wu G, Gu YW, Chen YJ, Huang CX: Effects of ghrelin on Cx43 regulation and electrical remodeling after myocardial infarction in rats. Peptides. 2011, 32: 2357-2361. 10.1016/j.peptides.2011.10.004.CrossRefPubMed
45.
Wen H, Jliang H, He B, Chen J, Zhao D: Carvedilol ameliorates the decreases in connexin 43 and ventricular fibrillation threshold in rats with myocardial infarction. Tohoku J Exp Med. 2009, 218: 121-127. 10.1620/tjem.218.121.CrossRefPubMed
46.
Peters NS, Coromilas J, Severs NJ, Wit AL: Disturbed connexin43 gap junction distribution correlates with the location of reentrant circuits in the epicardial border zone of healing canine infarcts that cause ventricular tachycardia. Circulation. 1997, 95: 988-996. 10.1161/01.CIR.95.4.988.CrossRefPubMed
47.
Peters NS, Green CR, Poole-Wilson PA, Severs NJ: Reduced content of connexin43 gap junctions in ventricular myocardium from hypertrophied and ischemic human hearts. Circulation. 1993, 88: 864-875. 10.1161/01.CIR.88.3.864.CrossRefPubMed
48.
Lindsey ML, Escobar GP, Mukherjee R, Goshorn DK, Bruce JA, Mains IM, Hendrick JK, Hewett KW, Gourdie RG, Matrisian LM, Spinale FG: Matrix metalloproteinase-7 affects connexin-43 levels, electrical conduction, and survival after myocardial infarction. Circulation. 2006, 113: 2919-2928. 10.1161/CIRCULATIONAHA.106.612960.CrossRefPubMed
49.
Lerner DL, Yamada KA, Schuessler RB, Saffitz JE: Accelerated onset and increased incidence of ventricular arrhythmias induced by ischemia in Cx43-deficient mice. Circulation. 2000, 101: 547-552. 10.1161/01.CIR.101.5.547.CrossRefPubMed
50.
Poelzing S, Rosenbaum DS: Altered connexin43 expression produces arrhythmia substrate in heart failure. Am J Physiol Heart Circ Physiol. 2004, 287: H1762-H1770. 10.1152/ajpheart.00346.2004.CrossRefPubMed
51.
Heras M, Sanz G, Roig E, Perez-Villa F, Recasens L, Serra A, Betriu A: Endothelial dysfunction of the non-infarct related, angiographically normal, coronary artery in patients with an acute myocardial infarction. Eur Heart J. 1996, 17: 715-720. 10.1093/oxfordjournals.eurheartj.a014938.CrossRefPubMed
52.
Uren NG, Crake T, Lefroy DC, de Silva R, Davies GJ, Maseri A: Reduced coronary vasodilator function in infarcted and normal myocardium after myocardial infarction. N Engl J Med. 1994, 331: 222-227. 10.1056/NEJM199407283310402.CrossRefPubMed
53.
Lakkisto P, Siren JM, Kyto V, Forsten H, Laine M, Pulkki K, Tikkanen I: Heme oxygenase-1 induction protects the heart and modulates cellular and extracellular remodelling after myocardial infarction in rats. Exp Biol Med. 2011, 326: 1437-1448.CrossRef
54.
L'Abbate A, Neglia D, Vecoli C, Novelli M, Ottaviano V, Baldi S, Barsacchi R, Paolicchi A, Masiello P, Drummond GS, McClung JA, Abraham NG: Beneficial effect of heme oxygenase-1 expression on myocardial ischemia-reperfusion involves an increase in adiponectin in mildly diabetic rats. Am J Physiol Heart Circ Physiol. 2007, 293: H3532-H3541. 10.1152/ajpheart.00826.2007.CrossRefPubMed
55.
Kusmic C, L'Abbate A, Sambuceti G, Drummond G, Barsanti C, Matteucci M, Cao J, Piccolomini F, Cheng J, Abraham NG: Myocardial perfusion in chronic diabetic mice by the up-regulation of pLKB1 and AMPK signaling. J Cell Biochem. 2010, 109: 1033-1044.PubMedCentralPubMed
56.
Schildknecht S, Ullrich V: Peroxynitrite as regulator of vascular prostanoid synthesis. Arch Biochem Biophys. 2009, 484: 183-189. 10.1016/j.abb.2008.10.023.CrossRefPubMed
Metadata
Title
Up-regulation of heme oxygenase-1 after infarct initiation reduces mortality, infarct size and left ventricular remodeling: experimental evidence and proof of concept
Authors
Claudia Kusmic
Cristina Barsanti
Marco Matteucci
Nicoletta Vesentini
Gualtiero Pelosi
Nader G Abraham
Antonio L’Abbate
Publication date
01-12-2014
Publisher
BioMed Central
Published in
Journal of Translational Medicine / Issue 1/2014
Electronic ISSN: 1479-5876
DOI
https://doi.org/10.1186/1479-5876-12-89

Other articles of this Issue 1/2014

Journal of Translational Medicine 1/2014 Go to the issue

Research

Comprehensive proteomic analysis of white blood cells from chikungunya fever patients of different severities

Research

De Novo modeling of Envelope 2 protein of HCV isolated from Pakistani patient and epitopes prediction for vaccine development

Research

A decrease in aquaporin 2 excretion is associated with bed rest induced high calciuria

Research

Differential hypoglycaemic, anorectic, autonomic and emetic effects of the glucagon-like peptide receptor agonist, exendin-4, in the conscious telemetered ferret

Erratum

Erratum to: novel anti-glioblastoma agents and therapeutic combinations identified from a collection of FDA approved drugs

Research

Systems level mapping of metabolic complexity in Mycobacterium tuberculosis to identify high-value drug targets
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Heart Failure Video

Year in Review: Heart failure and cardiomyopathies

Watch now

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits